Which agent is considered a first-line pharmacologic treatment for osteoporosis?

Which agent is considered a first-line pharmacologic treatment for osteoporosis?

• A. Calcitonin
• B. Teriparatide
• C. Denosumab
• D. Bisphosphonates (eg, alendronate)

Answer: (D)

Bisphosphonates are first-line because they strongly inhibit osteoclast-mediated bone resorption, slowing bone loss and increasing bone density. This antiresorptive effect translates into a well-established, substantial reduction in fracture risk (vertebral and nonvertebral) across many patients with osteoporosis. They have the most robust and long-standing clinical trial data supporting fracture outcomes, are generally cost-effective, and are available in convenient oral forms (with IV options for those who can’t take pills). Other agents—such as calcitonin (weaker efficacy and less fracture protection), teriparatide (an anabolic therapy reserved for very high-risk or refractory cases), and denosumab (effective but typically used when bisphosphonates are unsuitable or after intolerance)—are important in certain scenarios but do not provide the same broad, first-line foundation as bisphosphonates.

Bisphosphonates are first-line because they strongly inhibit osteoclast-mediated bone resorption, slowing bone loss and increasing bone density. This antiresorptive effect translates into a well-established, substantial reduction in fracture risk (vertebral and nonvertebral) across many patients with osteoporosis. They have the most robust and long-standing clinical trial data supporting fracture outcomes, are generally cost-effective, and are available in convenient oral forms (with IV options for those who can’t take pills). Other agents—such as calcitonin (weaker efficacy and less fracture protection), teriparatide (an anabolic therapy reserved for very high-risk or refractory cases), and denosumab (effective but typically used when bisphosphonates are unsuitable or after intolerance)—are important in certain scenarios but do not provide the same broad, first-line foundation as bisphosphonates.